|
|
|
LifeScienceHistory.com - Check us out on Instagram
Montana Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MontanaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
SiteOne Therapeutics Inc.
| | | Phone: | (406) 577-2173 | Year Established: | 2010 | Main Contact: | Stan E. Abel, President & CEO | | Other Contacts: | Debra Odink, Ph.D., Chief Development Officer Hassan Pajouhesh, Ph.D., Director, Chemistry Anton Delwig, Ph.D., Principal Scientist John Mulcahy, Ph.D., Co-inventor, VP of Research
| | Company Description | SiteOne Therapeutics was founded with technology invented at Stanford University that represents a potential revolutionary advancement in the treatment of acute and chronic pain. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (Na?1.7) inhibitors based on naturally occurring small molecules. Given the critical role Na?1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead product for the treatment of moderate to severe pain. Additional opportunities with the company’s technology include long-acting analgesics, PET imaging diagnostics for pain and other pain indications. SiteOne owns worldwide development and commercialization rights to its development programs through an exclusive license from Stanford University. | |
|
|
|
|
|